A5059910743- Acute Myeloid Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Chronic Myeloid Leukemia Treatments
- Epigenetics and DNA Methylation
- Acute Lymphoblastic Leukemia research
- Protein Degradation and Inhibitors
- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Histone Deacetylase Inhibitors Research
- Hematopoietic Stem Cell Transplantation
- Multiple Myeloma Research and Treatments
- Lung Cancer Research Studies
- Lung Cancer Treatments and Mutations
- Hemoglobinopathies and Related Disorders
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms
- Pluripotent Stem Cells Research
- NF-κB Signaling Pathways
- Bone and Joint Diseases
- Medical History and Research
- Kruppel-like factors research
- BRCA gene mutations in cancer
- Neutropenia and Cancer Infections
- Chemotherapy-induced cardiotoxicity and mitigation
- Immune Response and Inflammation
Cleveland Clinic
2016-2025
The University of Texas MD Anderson Cancer Center
2023
University Hospital Leipzig
2023
Moffitt Cancer Center
2023
Cerner (United States)
2019
Nucleophosmin (NPM1) mutations are common in acute myeloid leukemia and associated with high remission rates prolonged survival intensive chemotherapy. NPM1 rare myelodysplastic syndromes (MDS) or myelodysplastic/myeloproliferative neoplasm (MDS/MPN), the clinical outcomes of these patients, when treated chemotherapy, unknown. We retrospectively evaluated clinicopathologic characteristics impact therapy 31 patients MDS MDS/MPN mutations. Next-generation sequencing was performed at diagnosis...
Patients with myelodysplastic syndromes (MDS) have a survival that can range from months to decades. Prognostic systems incorporate advanced analytics of clinical, pathologic, and molecular data the potential more accurately dynamically predict in patients receiving various therapies.A total 1,471 MDS comprehensively annotated clinical were included training cohort analyzed using machine learning techniques. A random algorithm was used build prognostic model, which then validated external...
Circulating tumor DNA (ctDNA) is emerging as a promising, non-invasive diagnostic and surveillance biomarker in solid organ malignancy. However, its utility before after liver transplant (LT) for patients with primary secondary cancers still underexplored.
The interferon (IFN) system represents the first line of defense against a wide range viruses. Virus infection rapidly triggers transcriptional induction IFN-β and IFN Stimulated Genes (ISGs), whose protein products act as viral restriction factors by interfering with specific stages virus life cycle, such entry, transcription, translation, genome replication, assembly egress. Here, we report new mode action an ISG, IFN-induced TDRD7 (tudor domain containing 7) inhibited paramyxovirus...
Abstract Myelodysplastic syndromes (MDS) arise in older adults through stepwise acquisitions of multiple somatic mutations. Here, analyzing 1809 MDS patients, we infer clonal architecture by using a stringent, the single-cell sequencing validated PyClone bioanalytic pipeline, and assess position mutations within architecture. All 3,971 are grouped based on their rank deduced hierarchy (dominant secondary). We evaluated how they affect resultant morphology, progression, survival response to...
Abstract Therapy-related myeloid neoplasms (tMN) are complications of cytotoxic therapies. Risk tMN is high in recipients autologous hematopoietic stem cell transplantation (aHSCT). Acquisition genomic mutations represents a key pathogenic driver but the origins, timing and dynamics, particularly context preexisting or emergent clonal hematopoiesis (CH), have not been sufficiently clarified. We studied cohort 1507 patients undergoing aHSCT 263 who developed without to determine...
Somatic TET2 mutations (TET2MT) are frequent in myeloid neoplasia (MN), particularly chronic myelomonocytic leukemia (CMML). TET2MT includes mostly loss-of-function/hypomorphic hits. Impaired activity skews differentiation of hematopoietic stem cells toward proliferating precursors. This study was prompted by the observation biallelic gene inactivations (biTET2i ) CMML. We speculated that biTET2i might be associated with distinct clinicohematological features. analyzed 1045 patients MN. Of...
Somatic mutations of the CUT-like homeobox 1 (CUX1) gene (CUX1MT) can be found in myeloid neoplasms (MNs), particular, myelodysplastic syndromes (MDSs). The CUX1 locus is also deleted 3 4 MN cases with -7/del(7q). A cohort 1480 patients was used to characterize clinical features and clonal hierarchy associated CUX1MT deletions (CUX1DEL) analyze their functional consequences vitro. were present 4% chronic MNs. CUX1DEL preferentially advanced (6%). Most MDS acute leukemia (AML) -7/del(7q) up...
The nucleoside analogue decitabine can deplete the epigenetic regulator DNA methyltransferase 1 (DNMT1), an effect that occurs, and is saturated at, low concentrations/doses. A reason to pursue this molecular-targeted instead of damage/cytotoxicity produced with high concentrations/doses, non-cytotoxic DNMT1-depletion cytoreduce even p53-null myeloid malignancies while sparing normal haematopoiesis. We thus identified minimum doses (0·1-0·2 mg/kg) DNMT1 without off-target anti-metabolite...
Cancer cohorts are now known to be associated with increased rates of clonal hematopoiesis (CH). We sort characterize the hematopoietic compartment patients melanoma and non-small cell lung cancer (NSCLC) given our recent population level analysis reporting evolving secondary leukemias. The advent immune checkpoint blockade (ICB) has dramatically changed understanding biology altered standards care for patients. However, impact ICB on myeloid expansion remains determined. studied if exposure...
Summary The therapy algorithm for severe aplastic anaemia (sAA) is established but moderate AA (mAA), which likely reflects a more diverse pathogenic mechanism, often represents treatment/management conundrum. A cohort of patients ( n = 325) was queried those with non‐severe disease using stringent criteria including bone marrow hypocellularity and chronic persistence moderately depressed blood counts. As result, we have identified analyzed pathological clinical features in 85 mAA patients....